ACTICOR BIOTECH SAS |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.27 EUR | -92.64% |
|
-93.33% | -90.69% |
| Apr. 25 | Acticor Biotech: Phase 2/3 study fails | CF |
| Apr. 25 | Acticor Biotech SAS Announces Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Acticor Biotech is specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms.
The group has one product in Phase II/III clinical development (Glenzocimab).
Calendar
2024-04-29
- Q4 2023 Earnings Release
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.27
EUR
Average target price
10
EUR
Spread / Average Target
+3,603.70%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -90.69% | 51.51M | |
| -2.26% | 104B | |
| +1.41% | 97.42B | |
| +0.79% | 22.2B | |
| -17.84% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -17.63% | 15.06B | |
| +4.55% | 13.98B | |
| +32.11% | 11.66B |
- Stock Market
- Equities
- ALACT Stock
- News Acticor Biotech SAS
- Acticor Biotech's Stroke Drug Cuts Risk Of Brain Bleeding, Death In Early-Stage Study
